Navigation Links
Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
Date:2/13/2009

d are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements. Factors that could affect actual results include risks associated with our ability to obtain future financing and fund the product development of our pipeline; our ability to estimate accurately the amount of cash to be used to fund operations; unexpected delays in clinical trials and preclinical studies and the timing for making related regulatory filings; the fact that data from preclinical studies and Phase 1 or Phase 2 clinical trials may not necessarily be indicative of future clinical trial results; the initiation, timing, design, enrollment and cost of clinical trials and preclinical studies; our ability to establish successful partnerships and collaborations with third parties; the regulatory approval process in the United States and other countries; and our future capital requirements. For further information about these risks and other factors that may affect the actual results achieved by Pharmacyclics, please see the company's reports as filed with the U.S. Securities and Exchange Commission from time to time, including but not limited to its annual report on Form 10-K for the period ended June 30, 2008 and its subsequently filed quarterly reports on Form 10-Q. Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

                          ---FINANCIALS ATTACHED---



                             Pharmacyclics, Inc.
                       (a development stage enterprise)
                      Condensed Statements of Operations
              (unaudited) (in thousands, except per share data)

                                        Three Months Ended  Six Months Ended
                                 
'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
2. Pharmacyclics Secures $5.0 Million in Debt Financing
3. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
4. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
5. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
6. Pharmacyclics Announces It Received Nasdaq Notification
7. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
8. YM BIOSCIENCES REPORTS SECOND QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS
9. Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results
10. Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results
11. Corgenix Reports Second Quarter Fiscal 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014 Amgen (NASDAQ: ... Directors today declared a $0.61 per share dividend for ... paid on Sept. 5, 2014, to all stockholders of ... 14, 2014.  About Amgen Amgen is ... suffering from serious illnesses by discovering, developing, manufacturing and ...
(Date:7/25/2014)... According to a new market report published ... Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 ... at USD 161,056.5 million in 2014 and is expected ... to 2020, to reach an estimated value of USD ... is witnessing a significant growth due to the increasing ...
(Date:7/25/2014)... , July 25, 2014  Galmed Pharmaceuticals Ltd. ... company focused on the development and commercialization of a ... and cholesterol gallstones, today announced financial results for the ... 2014 Financial Summary: , Reported cash and cash ... with $137,000 at December 31, 2013.  , Reported ...
(Date:7/24/2014)... July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the ... randomized, active control Phase 3 study of Zerenex (ferric ... for the treatment of hyperphosphatemia in patients with end-stage ... binding and iRon delivery with FErric CiTrate in EsrD) ... the American Society of Nephrology ( JASN ). ...
Breaking Biology Technology:Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4
... BEIJING , May 10 /PRNewswire-Asia-FirstCall/ -- Yongye International, Inc.,(Nasdaq: ... Shengmingsu brand plant and animal nutrient products in the,People,s Republic of ... four investment conferences in May 2010 . , ... The date, time and ...
... BEIJING , May 10 /PRNewswire-Asia-FirstCall/ -- Yongye International, Inc.,(Nasdaq: ... distributor of Shengmingsu brand plant and animal nutrient products in ... has started,the construction of a new production facility in Wuchuan County, ... , , ...
... ... LASIK Surgeons launched its revolutionary Trusted LASIK Surgeons directory service and website ... seeking to improve their vision and find a highly qualified eye surgeon ... sets the Trusted LASIK Surgeons directory apart is a unique screening process ...
Cached Biology Technology:Yongye International to Present at Upcoming Investor Conferences 2Yongye International to Present at Upcoming Investor Conferences 3Yongye International, Inc. Begins Construction of New Production Facility 2Yongye International, Inc. Begins Construction of New Production Facility 3Yongye International, Inc. Begins Construction of New Production Facility 4Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 2Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 3Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 4Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 5Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 6Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 7Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 8Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 9
(Date:7/27/2014)... RESEARCH UK scientists at Barts Cancer Institute have found ... cancer therapy significantly more effective, according to research published ... Barts Cancer Institute, part of Queen Mary University of ... kinase (FAK), signals the body to repair itself after ... DNA. When the researchers removed FAK from blood vessels ...
(Date:7/25/2014)... 25, 2014 In the first broad-scale estimate of air ... and collaborators calculated that trees are saving more than ... of acute respiratory symptoms. , While trees, pollution removal ... than 1 percent, the impacts of that improvement are ... reduced air pollution at nearly $7 billion every year ...
(Date:7/25/2014)... been raging this summer and some of the smoke from ... this image collected by the Moderate Resolution Imaging Spectroradiometer (MODIS) ... of smoke has descended over the Great Lakes region of ... fire image from July 23, 2014 (first image feature highlighted ... drifts off southeastward. In the image, it is over ...
Breaking Biology News(10 mins):New drug target can break down cancer's barrier against treatment 2First national study finds trees saving lives, reducing respiratory problems 2
... Sheng Yang He, plant biologist at Michigan State ... plant scientists as part of a $75 million new ... Institute and the Gordon and Betty Moore Foundation honored ... and 14 other researchers from around the country. The ...
... Spring Harbor, N.Y. The Howard Hughes Medical Institute (HHMI) ... selected Professor Rob Martienssen, Ph.D., of Cold Spring Harbor ... basic research in fundamental plant science. Dr. Martienssen is ... scientists who have been named HHMI-GBMF Investigators in plant ...
... Md. (June 16, 2011) Coaches, physiologists and athletes ... before athletic competition. Warming up increases muscle temperature, accelerates ... which enhance performance. However, the question of how long ... with some in the sports community advocating longer warm-ups ...
Cached Biology News:MSU plant scientist named one of the nation's most innovative researchers 2CSHL professor Rob Martienssen receives prestigious appointment as HHMI-GBMF investigator 2CSHL professor Rob Martienssen receives prestigious appointment as HHMI-GBMF investigator 3CSHL professor Rob Martienssen receives prestigious appointment as HHMI-GBMF investigator 4When warming up for the cycling race, less is more 2When warming up for the cycling race, less is more 3
Request Info...
IHC Detection Kit (Broad Spectrum AEC)....
... Dissociation Buffers are membrane-filtered isotonic and ... agents and cell-conditioning agents in either ... solution or Ca2+- and Mg2+-free ... mammalian cells from support substrates and ...
Request Info...
Biology Products: